| Sanofi still pursuing offer to acquire Genzyme. |
|
| Wall Street Journal: Sanofi-Aventis SA has proposed paying Genzyme Corp. in the range of $74 a share in cash upfront as the two parties push to sign a deal in about a week, people familiar with the matter said. That would value the biotech company at around $19 billion. |